Esperion Therapeutics Stock Forecast, Price & News

Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions

Is Esperion Therapeutics a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 2 sell ratings, 5 hold ratings, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Esperion Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESPR, but not buy additional shares or sell existing shares.
View analyst ratings for Esperion Therapeutics or view top-rated stocks.

How has Esperion Therapeutics' stock been impacted by Coronavirus?

Esperion Therapeutics' stock was trading at $42.93 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ESPR shares have decreased by 79.1% and is now trading at $8.97.
View which stocks have been most impacted by COVID-19.

When is Esperion Therapeutics' next earnings date?

Esperion Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, February 22nd 2022.
View our earnings forecast for Esperion Therapeutics.

How were Esperion Therapeutics' earnings last quarter?

Esperion Therapeutics, Inc. (NASDAQ:ESPR) posted its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported ($2.62) EPS for the quarter, topping the consensus estimate of ($2.86) by $0.24. The biopharmaceutical company earned $14.41 million during the quarter, compared to analysts' expectations of $12.31 million. During the same period in the previous year, the firm earned ($3.07) earnings per share.
View Esperion Therapeutics' earnings history.

What price target have analysts set for ESPR?

10 Wall Street analysts have issued 12-month price targets for Esperion Therapeutics' stock. Their forecasts range from $8.00 to $114.00. On average, they anticipate Esperion Therapeutics' stock price to reach $40.36 in the next twelve months. This suggests a possible upside of 350.0% from the stock's current price.
View analysts' price targets for Esperion Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Esperion Therapeutics' key executives?

Esperion Therapeutics' management team includes the following people:

• Sheldon L. Koenig, President, Chief Executive Officer & Director
• Rick Bartram, Chief Financial Officer
• JoAnne Micale Foody, Chief Medical Officer
• Ken Fiorelli, Chief Technical Operations Officer
• William J. Sasiela, Senior Vice President-Clinical Development

What is Tim Mayleben's approval rating as Esperion Therapeutics' CEO?

20 employees have rated Esperion Therapeutics CEO Tim Mayleben on Glassdoor.com. Tim Mayleben has an approval rating of 80% among Esperion Therapeutics' employees.

Who are some of Esperion Therapeutics' key competitors?

Some companies that are related to Esperion Therapeutics include CannTrust (CNTTF), Nuvalent (NUVL), Merus (MRUS), Arcturus Therapeutics (ARCT), PMV Pharmaceuticals (PMVP), Amphastar Pharmaceuticals (AMPH), Heron Therapeutics (HRTX), RAPT Therapeutics (RAPT), Zymeworks (ZYME), Vanda Pharmaceuticals (VNDA), Repare Therapeutics (RPTX), Zealand Pharma A/S (ZEAL), BELLUS Health (BLUSF), Generation Bio (GBIO) and Kura Oncology (KURA).
View all of ESPR's competitors.

What other stocks do shareholders of Esperion Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Esperion Therapeutics investors own include ALDW (ALDW), Targa Resources (TRGP), Navios Maritime Partners (NMM), NVIDIA (nvda), Micron Technology (MU), SFL (SFL), Gilead Sciences (GILD), Boeing (BA), Alibaba Group (BABA) and BioMarin Pharmaceutical (bmrn).

What is Esperion Therapeutics' stock symbol?

Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."

Who are Esperion Therapeutics' major shareholders?

Esperion Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Wasatch Advisors Inc. (11.26%), BlackRock Inc. (6.90%), Rhenman & Partners Asset Management AB (2.14%), Marshall Wace LLP (1.79%), Millennium Management LLC (1.61%) and Morgan Stanley (1.55%). Company insiders that own Esperion Therapeutics stock include Target N V Biotech and Timothy M Mayleben.
View institutional ownership trends for Esperion Therapeutics.

Which institutional investors are selling Esperion Therapeutics stock?

ESPR stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Wasatch Advisors Inc., Cinctive Capital Management LP, Citigroup Inc., Caption Management LLC, Geode Capital Management LLC, Caas Capital Management LP, and BlackRock Inc..
View insider buying and selling activity for Esperion Therapeutics or view top insider-selling stocks.

Which institutional investors are buying Esperion Therapeutics stock?

ESPR stock was purchased by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Voloridge Investment Management LLC, Credit Suisse AG, Millennium Management LLC, Cubist Systematic Strategies LLC, Linden Advisors LP, Russell Investments Group Ltd., and SG Americas Securities LLC. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech, and Timothy M Mayleben.
View insider buying and selling activity for Esperion Therapeutics or or view top insider-buying stocks.

How do I buy shares of Esperion Therapeutics?

Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Esperion Therapeutics' stock price today?

One share of ESPR stock can currently be purchased for approximately $8.97.

How much money does Esperion Therapeutics make?

Esperion Therapeutics has a market capitalization of $260.82 million and generates $227.55 million in revenue each year. The biopharmaceutical company earns $-143.55 million in net income (profit) each year or ($11.68) on an earnings per share basis.

How many employees does Esperion Therapeutics have?

Esperion Therapeutics employs 479 workers across the globe.

What is Esperion Therapeutics' official website?

The official website for Esperion Therapeutics is www.esperion.com.

Where are Esperion Therapeutics' headquarters?

Esperion Therapeutics is headquartered at 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108.

How can I contact Esperion Therapeutics?

Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at (734) 887-3903 or via email at [email protected].